Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract, published online September 2014. DOI: 10.1177/1078155214551315
J Oncol Pharm Pract
.
2015 Aug;21(4):318-9.
doi: 10.1177/1078155215585051.
Epub 2015 May 15.
Authors
Derya Hopanci Bicakli
1
,
Umut Varol
2
,
Mustafa Degirmenci
1
,
Didem Tunali
1
,
Burcu Cakar
1
,
Raika Durusoy
3
,
Burcak Karaca
1
,
Ulus Ali Sanli
1
,
Ruchan Uslu
1
Affiliations
1
Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Turkey.
2
Division of Medical Oncology, Tulay Aktas Oncology Hospital, School of Medicine, Ege University, Turkey varolumut@yahoo.com.
3
Department of Public Health, School of Medicine, Ege University, Turkey.
PMID:
25979298
DOI:
10.1177/1078155215585051
No abstract available
Publication types
Letter
Comment
MeSH terms
Breast Neoplasms / drug therapy*
Chemotherapy, Adjuvant / adverse effects*
Female
Humans
Metabolic Syndrome / chemically induced*
Metabolic Syndrome / diagnosis*